ONCT Oncternal Therapeutics Inc
Price (delayed)
$4.07
Market cap
$12.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.15
Enterprise value
$5.9M
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on
Highlights
The gross profit has soared by 114% YoY and by 60% from the previous quarter
ONCT's revenue has surged by 114% year-on-year and by 60% since the previous quarter
The quick ratio has plunged by 72% YoY and by 40% from the previous quarter
ONCT's equity has plunged by 65% YoY and by 31% from the previous quarter
Key stats
What are the main financial stats of ONCT
Market
Valuations
Earnings
Shares outstanding
2.96M
Market cap
$12.05M
Enterprise value
$5.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
6.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
Revenue
$1.85M
EBIT
-$35.97M
EBITDA
-$35.81M
Free cash flow
-$25.19M
Per share
Balance sheet
Liquidity
EPS
-$12.15
Free cash flow per share
-$8.51
Book value per share
$5.32
Revenue per share
$0.62
TBVPS
$8.06
Total assets
$23.86M
Total liabilities
$8.11M
Debt
$235,000
Equity
$15.75M
Working capital
$15.2M
Debt to equity
0.01
Current ratio
2.89
Quick ratio
2.66
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-1,939.6%
Gross margin
100%
Net margin
-1,948.7%
Operating margin
-2,040.5%
Return on assets
-108.3%
Return on equity
-136.1%
Return on invested capital
-191.4%
Return on capital employed
-227.6%
Return on sales
-1,948.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ONCT stock price
How has the Oncternal Therapeutics stock price performed over time
Intraday
2.26%
1 week
-0.97%
1 month
-22.48%
1 year
-34.35%
YTD
-62.03%
QTD
-46.45%
Financial performance
How have Oncternal Therapeutics's revenue and profit performed over time
Revenue
$1.85M
Gross profit
$1.85M
Operating income
-$37.67M
Net income
-$35.97M
Gross margin
100%
Net margin
-1,948.7%
The gross profit has soared by 114% YoY and by 60% from the previous quarter
ONCT's revenue has surged by 114% year-on-year and by 60% since the previous quarter
Oncternal Therapeutics's net margin has soared by 61% YoY and by 38% from the previous quarter
The operating margin has surged by 61% year-on-year and by 39% since the previous quarter
Growth
What is Oncternal Therapeutics's growth rate over time
Valuation
What is Oncternal Therapeutics stock price valuation
P/E
N/A
P/B
0.76
P/S
6.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
The EPS is up by 20% year-on-year
ONCT's equity has plunged by 65% YoY and by 31% from the previous quarter
ONCT's price to book (P/B) is 60% less than its 5-year quarterly average of 1.9 and 24% less than its last 4 quarters average of 1.0
ONCT's revenue has surged by 114% year-on-year and by 60% since the previous quarter
ONCT's price to sales (P/S) is 80% lower than its 5-year quarterly average of 32.0 and 74% lower than its last 4 quarters average of 25.6
Efficiency
How efficient is Oncternal Therapeutics business performance
ONCT's return on equity has dropped by 80% year-on-year and by 26% since the previous quarter
The return on sales has surged by 61% year-on-year and by 38% since the previous quarter
The return on assets has dropped by 60% year-on-year and by 19% since the previous quarter
The return on invested capital has declined by 26% since the previous quarter and by 4.7% year-on-year
Dividends
What is ONCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ONCT.
Financial health
How did Oncternal Therapeutics financials performed over time
The company's total assets is 194% higher than its total liabilities
The current ratio has plunged by 72% YoY and by 38% from the previous quarter
The quick ratio has plunged by 72% YoY and by 40% from the previous quarter
Oncternal Therapeutics's debt is 99% less than its equity
ONCT's equity has plunged by 65% YoY and by 31% from the previous quarter
Oncternal Therapeutics's debt has decreased by 36% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.